Patents Assigned to Johannes Gutenberg—Universitat
  • Enhancing the effect of car-engineered T cells by means of nucleic acid vaccination
    Patent number: 10799534
    Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to a method for stimulating, priming and/or expanding in vivo T cells genetically modified to express a chimeric antigen receptor (CAR) targeted to an antigen, comprising contacting the T cells with the antigen or a variant thereof in vivo. In one embodiment, the antigen or variant thereof is provided by administering a nucleic acid encoding the antigen or variant thereof.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: October 13, 2020
    Assignees: BIONTECH CELL & GENE THERAPIES GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÁTSMEDIZIN DER JOHANNES GUTENBERG—UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
    Inventors: Ugur Sahin, Katharina Reinhard, Petra Simon, Karolina Anna Mroz, Kathleen Hobohm
  • Method and kit for determining whether a subject shows an immune response
    Patent number: 10550430
    Abstract: The present invention relates to a kit and a method for determining whether a subject shows an immune response against an antigen.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: February 4, 2020
    Assignees: BIONTECH DIAGNOSTICS GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG—UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Michael Schäfer, Marta Magdalena Faryna, Tana Omokoko, Lisa Hebich, Petra Simon, Annett Reichardt, Özlem Öz
  • Antibodies against claudin 18.2 useful in cancer diagnosis
    Patent number: 10053512
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: August 21, 2018
    Assignees: GANYMED PHARMACEUTICALS AG, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG—UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll
  • Use of FLT3 ligand for enhancing immune responses in RNA immunization
    Patent number: 9486519
    Abstract: The invention relates to supplying vaccine RNA to cells. The invention relates in particular to a common use of vaccine RNA and Flt3 ligand for inducing, creating or enhancing an immune response when administered to animals (including humans).
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: November 8, 2016
    Assignees: BioNTech AG, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg—Universität Mainz gemeinnützige GmbH
    Inventors: Ugur Sahin, Özlem Türeci, Sebastian Kreiter, Abderraouf Selmi
  • 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
    Patent number: 9012659
    Abstract: The present invention relates to a compound of formula (I) wherein R1, R2 and R3 are as defined in the description and the physiologically acceptable salts thereof as well as the physiologically acceptable solvates of the compounds of formula I and of the salts thereof. The compounds of formula I are suitable for treating tumors.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: April 21, 2015
    Assignee: Johannes Gutenberg—Universitat Mainz
    Inventors: Gerd Dannhardt, Jan-Peter Kramb, Stanislav Plutizki
  • Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
    Patent number: 8957103
    Abstract: The present invention relates to 3-(Indolyl)- and 3-(azaindolyl)-4-phenylmaleimide compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, and the physiologically acceptable salts, solvates and solvates of the salts of the compounds of formula (I). The compounds of formula (I) are suitable for treating tumors.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: February 17, 2015
    Assignee: Johannes Gutenberg—Universitat Mainz
    Inventors: Gerd Dannhardt, Stanislav Plutizki, Christopher Ganser, Eva Lauermann
  • Monoclonal antibodies for treatment of cancer
    Patent number: 8354104
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: January 15, 2013
    Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg—Universitat
    Inventors: Ugur Sahin, Michael Koslowski, Ozlem Tureci